A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Relapsed/Refractory Multiple Myeloma Clinical Trial

Official title:

A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABBV-383 Monotherapy in Japanese Subjects With Relapsed or Refractory Multiple Myeloma (4L+ RRMM Monotherapy Study)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05286229
• Other study ID #: M22-984
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: March 24, 2022
• Est. completion date: March 30, 2025

Study information

• Verified date: June 2024
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multiple myeloma (MM) is an incurable disease characterized by the growth of monoclonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease state of ABBV-383 in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed.

ABBV-383 is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Two doses of ABBV-383 will be explored. Each treatment arm receives a different dose of ABBV-383 to determine a tolerable dose. Approximately 12 adult participants with R/R MM will be enrolled in the study in approximately 6 sites in Japan.

Participants will receive intravenous (IV) ABBV-383 at two increasing doses in 21-day cycles.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and and monitoring of side effects.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 8
• Est. completion date: March 30, 2025
• Est. primary completion date: March 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance of <= 2.

• Must have adequate bone marrow function as defined in the protocol.

• Must meet laboratory parameters as outlined in the protocol.

• Must have a confirmed diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the International Myeloma Working group (IMWG) criteria.

• Relapsed defined as previously treated myeloma that progresses and requires initiation of salvage therapy, but does not meet criteria for refractory myeloma.

• Refractory defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy, or progresses within 60 days of last therapy.

• Must have received at least 3 prior lines of therapy (including exposure to a proteasome inhibitor (PI), an immunomodulatory imide (IMiD), and an anti-CD38 mAb).

• Must have measurable disease within 28 days of enrollment, defined as at least 1 of the following:

• Serum M-protein >= 0.5 g/dL (>= 5 g/L).

• Urine M-protein >= 200 mg/24 hours.

• Serum free light chain (FLC) >= 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio only for participants without measurable serum or urine M-protein.

• Consents to a fresh pretreatment bone marrow tumor biopsy or has adequate archival bone marrow tumor tissue that was collected within 12 weeks prior to screening and without intervening treatment.

Exclusion Criteria:

• Has received B-cell maturation antigen (BCMA)-targeted therapy. Participants who have received targeted therapy against non-BCMA targets will not be excluded.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Relapsed/Refractory Multiple Myeloma

Intervention

Drug:
• ABBV-383
Intravenous (IV) Infusion

Locations

Country	Name	City	State
Japan	Kanazawa University Hospital /ID# 240948	Kanazawa-shi	Ishikawa
Japan	National Cancer Center Hospital East /ID# 240943	Kashiwa-shi	Chiba
Japan	Okayama Medical Center /ID# 240949	Okayama-shi	Okayama
Japan	Hokkaido University Hospital /ID# 242672	Sapporo-shi	Hokkaido
Japan	Osaka University Hospital /ID# 242032	Suita-shi	Osaka
Japan	Yamagata University Hospital /ID# 240945	Yamagata-shi	Yamagata

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Dose-Limiting Toxicities (DLT)	DLT events are defined as adverse events or abnormal laboratory values assessed as "reasonable possibility" of relationship to the administration of ABBV-383, which cannot be attributed by the investigator to a clearly identifiable cause such as disease progression or concurrent illness.	Up to Approximately 12 Months
Primary	Number of Participants with Adverse Events (AE)	AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.	Up to Approximately 24 Months
Secondary	Objective Response Rate (ORR)	ORR is defined as the percentage of participants who achieve confirmed partial response (PR) or better determined by International Myeloma Working Group (IMWG) criteria, prior to the initiation of subsequent myeloma therapy.	Up to Approximately 24 Months
Secondary	Progression Free Survival (PFS)	PFS is defined as the duration from the date of first dose to the date of disease progression (PD) determined by IMWG criteria, or death, whichever occurs first.	Up to Approximately 24 Months
Secondary	Time to Response (TTR)	TTR is defined as the number of months from the date of first dose to the date of best overall response of CR or PR ('responders') determined by IMWG criteria as assessed by investigator.	Up to Approximately 24 Months
Secondary	Duration of Response (DOR)	DOR is defined as the number of days from the day the response criteria are met to the date that disease progression is objectively documented.	Up to Approximately 24 Months
Secondary	Minimal Residual Disease (MRD) Negativity Rate	MRD is defined as the percentage of participants with assessment of the minimal residual disease negativity.	Up to Approximately 24 Months